These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results
Avi Kapoor 1 hour ago
MarketsTrading IdeasNewsAnalyst RatingsPrice TargetEarnings
OptimizeRx beat Q3 earnings and sales estimates but cut FY2026 revenue guidance; shares fell 17.3% as analysts lowered price targets.
OptimizeRx Corporation (NASDAQ:OPRX) reported upbeat earnings for the third quarter, but lowered its sales guidance on Wednesday.
The company posted quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $21.615 million which beat the analyst consensus estimate of $21.188 million.
OptimizeRx cut its FY2026 sales guidance from $95.000 million-$100.000 million to $87.000 million-$93.000 million.
Stephen L. Silvestro, OptimizeRx CEO said, “Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
OptimizeRx shares dipped 17.3% to trade at $7.40 on Thursday.
These analysts made changes to their price targets on OptimizeRx following earnings announcement.
- Stifel analyst David Grossman maintained the stock with a Buy and lowered the price target from $12 to $11.
- B. Riley Securities analyst Josh Nichols reiterated the stock with a Buy and lowered the price target from $11 to $10.5.
Considering buying OPRX stock? Here’s what analysts think:
Photo via Shutterstock